Loading
Hopec Pharma is an Israeli company developing an immune treatment for early bladder cancer made from an inactivated, genetically modified E. coli bacterium. It is in a first trial in people whose cancer came back after BCG or chemotherapy in the bladder.
Hopec Pharma, of Givat Shmuel, Israel, develops Inactivated UPEC-FimON, an immunotherapy based on a genetically modified uropathogenic Escherichia coli for non-muscle invasive bladder cancer; Estee Rosen is co-founder and chief executive. The company describes partnerships with the Hebrew University, Hadassah and Sheba. Its first registered cancer trial, NCT07881666, an open-label multicentre phase 1 study of intravesical inactivated UPEC-FimON in non-muscle invasive urothelial carcinoma after failure of BCG or intravesical chemotherapy, at Kfar Saba, Jerusalem and Ramat Gan, was posted on ClinicalTrials.gov in October 2026; the registry gives its start as October 2025.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/